Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Karl Ulrich Bayer

InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM - Pharmacology

    Collapse Research 
    Collapse research activities and funding
    R03NS050120     (BAYER, K. ULRICH)Jul 15, 2005 - Jun 30, 2007
    Cell-permeable inibitors specific for CaMKII
    Role: Principal Investigator

    R21DK070735     (BAYER, K. ULRICH)Feb 1, 2006 - Jan 31, 2009
    CaMKII signaling in insulin secretion and response
    Role: Principal Investigator

    R01NS052644     (BAYER, K. ULRICH)Jan 30, 2007 - Nov 30, 2012
    Structural and Catalytic Functions of CaMKII in Neurons
    Role: Principal Investigator

    R01NS080851     (HERSON, PACO S)May 1, 2013 - Apr 30, 2018
    CaMKII in global cerebral ischemia
    Role: Co-Investigator

    R01NS081248     (BAYER, K. ULRICH)Jul 1, 2013 - Mar 31, 2021
    CaMKII autophosphorylation in opposing directions of synaptic plasticity
    Role: Principal Investigator

    R21DA036300     (BAYER, K. ULRICH)Aug 1, 2013 - Jul 31, 2015
    Persistent reversal of addiction behavior by a transient treatment
    Role: Principal Investigator

    R21NS095760     (BAYER, K. ULRICH)Sep 1, 2016 - Aug 31, 2018
    Restoring synaptic function in Down Syndrome mice
    Role: Principal Investigator

    U01NS094261     (BAYER, K. ULRICH)Mar 1, 2017 - Feb 29, 2020
    A strategy for pharmacological treatment of global cerebral ischemia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives Aß Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 Jun 12; 23(11):3137-3145. PMID: 29898386.
      View in: PubMed
    2. Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIa and ß splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Sci Rep. 2018 Apr 03; 8(1):5448. PMID: 29615706.
      View in: PubMed
    3. Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the depalmitoylation and synaptic removal of the scaffold protein AKAP79/150 to mediate structural long-term depression. J Biol Chem. 2018 02 02; 293(5):1551-1567. PMID: 29196604.
      View in: PubMed
    4. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243. PMID: 28614711.
      View in: PubMed
    5. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742. PMID: 28589927.
      View in: PubMed
    6. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117. PMID: 28147268.
      View in: PubMed
    7. Dosemeci A, Toy D, Burch A, Bayer KU, Tao-Cheng JH. CaMKII-mediated displacement of AIDA-1 out of the postsynaptic density core. FEBS Lett. 2016 09; 590(17):2934-9. PMID: 27477489.
      View in: PubMed
    8. Goodell DJ, Benke TA, Bayer KU. Developmental restoration of LTP deficits in heterozygous CaMKIIa KO mice. J Neurophysiol. 2016 11 01; 116(5):2140-2151. PMID: 27535377.
      View in: PubMed
    9. Khan S, Conte I, Carter T, Bayer KU, Molloy JE. Multiple CaMKII Binding Modes to the Actin Cytoskeleton Revealed by Single-Molecule Imaging. Biophys J. 2016 Jul 26; 111(2):395-408. PMID: 27463141; PMCID: PMC4968397 [Available on 07/26/17].
    10. Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B Protein Interaction Maintains Synaptic Strength. J Biol Chem. 2016 07 29; 291(31):16082-9. PMID: 27246855; PMCID: PMC4965558 [Available on 07/29/17].
    11. Barcomb K, Goodell DJ, Arnold DB, Bayer KU. Live imaging of endogenous Ca²?/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity. J Neurochem. 2015 Nov; 135(4):666-73. PMID: 26212614; PMCID: PMC4636925 [Available on 11/01/16].
    12. Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6. PMID: 25447522; PMCID: PMC4312479.
    13. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. NMDA-induced accumulation of Shank at the postsynaptic density is mediated by CaMKII. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):808-11. PMID: 24952157.
      View in: PubMed
    14. Thein S, Pham A, Bayer KU, Tao-Cheng JH, Dosemeci A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):550-4. PMID: 24928390.
      View in: PubMed
    15. Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014 Jul 11; 289(28):19458-65. PMID: 24855644; PMCID: PMC4094056.
    16. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9. PMID: 24843070; PMCID: PMC4101658.
    17. Goodell DJ, Eliseeva TA, Coultrap SJ, Bayer KU. CaMKII binding to GluN2B is differentially affected by macromolecular crowding reagents. PLoS One. 2014; 9(5):e96522. PMID: 24796865; PMCID: PMC4010494.
    18. Bernard PB, Castano AM, Bayer KU, Benke TA. Necessary, but not sufficient: insights into the mechanisms of mGluR mediated long-term depression from a rat model of early life seizures. Neuropharmacology. 2014 Sep; 84:1-12. PMID: 24780380; PMCID: PMC4086946.
    19. Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP. NMDA receptor activation strengthens weak electrical coupling in mammalian brain. Neuron. 2014 Mar 19; 81(6):1375-1388. PMID: 24656255; PMCID: PMC4266555.
    20. Thein S, Tao-Cheng JH, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One. 2014; 9(3):e91312. PMID: 24614225; PMCID: PMC3948843.
    21. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7. PMID: 24485660; PMCID: PMC3930569.
    22. Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, Bayer KU. Excitotoxic glutamate insults block autophagic flux in hippocampal neurons. Brain Res. 2014 Jan 13; 1542:12-9. PMID: 24505621; PMCID: PMC3934833.
    23. Liu X, Liu Y, Zhong P, Wilkinson B, Qi J, Olsen CM, Bayer KU, Liu QS. CaMKII activity in the ventral tegmental area gates cocaine-induced synaptic plasticity in the nucleus accumbens. Neuropsychopharmacology. 2014 Mar; 39(4):989-99. PMID: 24154664; PMCID: PMC3924533.
    24. Barcomb K, Coultrap SJ, Bayer KU. Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol. 2013 Dec; 84(6):834-43. PMID: 24056996; PMCID: PMC3834147.
    25. Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-a1 and -a2 at the postsynaptic density. PLoS One. 2013; 8(8):e71795. PMID: 23967245; PMCID: PMC3742523.
    26. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience. 2013 Aug 06; 244:188-96. PMID: 23583761.
      View in: PubMed
    27. Loweth JA, Li D, Cortright JJ, Wilke G, Jeyifous O, Neve RL, Bayer KU, Vezina P. Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition. J Neurosci. 2013 Jan 23; 33(4):1411-6. PMID: 23345217; PMCID: PMC3710147.
    28. Boguslavsky S, Chiu T, Foley KP, Osorio-Fuentealba C, Antonescu CN, Bayer KU, Bilan PJ, Klip A. Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles. Mol Biol Cell. 2012 Oct; 23(20):4065-78. PMID: 22918957; PMCID: PMC3469521.
    29. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012 Oct; 35(10):607-18. PMID: 22717267; PMCID: PMC3461103.
    30. Coultrap SJ, Barcomb K, Bayer KU. A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One. 2012; 7(5):e37176. PMID: 22615928; PMCID: PMC3353915.
    31. Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245. PMID: 21984908; PMCID: PMC3184957.
    32. O'Leary H, Liu WH, Rorabaugh JM, Coultrap SJ, Bayer KU. Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. J Biol Chem. 2011 Sep 09; 286(36):31272-81. PMID: 21768120; PMCID: PMC3173099.
    33. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci. 2011 Jun 22; 31(25):9170-8. PMID: 21697368; PMCID: PMC3138556.
    34. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72. PMID: 21685929; PMCID: PMC3846291.
    35. Marsden KC, Shemesh A, Bayer KU, Carroll RC. Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proc Natl Acad Sci U S A. 2010 Nov 23; 107(47):20559-64. PMID: 21059908; PMCID: PMC2996683.
    36. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20. PMID: 20554872.
      View in: PubMed
    37. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82. PMID: 20424167; PMCID: PMC2898334.
    38. Cipolletta E, Monaco S, Maione AS, Vitiello L, Campiglia P, Pastore L, Franchini C, Novellino E, Limongelli V, Bayer KU, Means AR, Rossi G, Trimarco B, Iaccarino G, Illario M. Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology. 2010 Jun; 151(6):2747-59. PMID: 20392834; PMCID: PMC2875822.
    39. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7. PMID: 20353941; PMCID: PMC2878555.
    40. Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett. 2009 Nov 19; 583(22):3577-81. PMID: 19840793; PMCID: PMC2790910.
    41. Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell. 2007 Dec; 18(12):5024-33. PMID: 17942605.
      View in: PubMed
    42. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther. 2007 May; 6(5):732-42. PMID: 17387273.
      View in: PubMed
    43. O'Leary H, Lasda E, Bayer KU. CaMKIIbeta association with the actin cytoskeleton is regulated by alternative splicing. Mol Biol Cell. 2006 Nov; 17(11):4656-65. PMID: 16928958.
      View in: PubMed
    44. O'Leary H, Sui X, Lin PJ, Volpe P, Bayer KU. Nuclear targeting of the CaMKII anchoring protein alphaKAP is regulated by alternative splicing and protein kinases. Brain Res. 2006 May 01; 1086(1):17-26. PMID: 16616897.
      View in: PubMed
    45. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006 Jan 25; 26(4):1164-74. PMID: 16436603; PMCID: PMC2890238.
    46. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, Rossi G, Vitale M. Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem. 2003 Nov 14; 278(46):45101-8. PMID: 12954639.
      View in: PubMed
    47. Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, Meyer T. Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron. 2003 Jul 17; 39(2):283-97. PMID: 12873385.
      View in: PubMed
    48. Nori A, Lin PJ, Cassetti A, Villa A, Bayer KU, Volpe P. Targeting of alpha-kinase-anchoring protein (alpha KAP) to sarcoplasmic reticulum and nuclei of skeletal muscle. Biochem J. 2003 Mar 15; 370(Pt 3):873-80. PMID: 12470297; PMCID: PMC1223226.
    49. Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H, Hell JW. Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem. 2002 Dec 13; 277(50):48441-8. PMID: 12379661.
      View in: PubMed
    50. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7. PMID: 12110572; PMCID: PMC126106.
    51. Bayer KU, Schulman H. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):917-23. PMID: 11741277.
      View in: PubMed
    52. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001 Jun 14; 411(6839):801-5. PMID: 11459059.
      View in: PubMed
    53. Bayer KU, Löhler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Res Mol Brain Res. 1999 Jun 18; 70(1):147-54. PMID: 10381553.
      View in: PubMed
    54. Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. EMBO J. 1998 Oct 01; 17(19):5598-605. PMID: 9755160; PMCID: PMC1170888.
    55. Bayer KU, Löhler J, Harbers K. An alternative, nonkinase product of the brain-specifically expressed Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. Mol Cell Biol. 1996 Jan; 16(1):29-36. PMID: 8524307; PMCID: PMC230975.
    Bayer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)